Gilead Sciences earnings were $6.0B for the trailing 12 months ending Mar 31, 2025, with 1,092.5% growth year over year. The latest GILD earnings report on Mar 31, 2025 announced Q1 2025 earnings of $1.3B, down 26.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GILD reported annual earnings of $480.0M, with -91.5% growth. The next GILD earnings date is Aug 5, 2025.
GILD past earnings growth
How has GILD's earnings growth performed historically?
What were Gilead Sciences's earnings last quarter?
On GILD's earnings call on Invalid Date, Gilead Sciences (NASDAQ: GILD) reported Q1 2025 earnings per share (EPS) of $1.06, up 131.74% year over year. Total GILD earnings for the quarter were $1.32 billion. In the same quarter last year, Gilead Sciences's earnings per share (EPS) was -$3.34.
The next GILD earnings call is Invalid Date. Add GILD to your watchlist to be reminded of Gilead Sciences's next earnings date.
Is Gilead Sciences profitable or losing money?
As of the last Gilead Sciences earnings report, Gilead Sciences is currently profitable. Gilead Sciences's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $5.97 billion, a 1,132.44% increase year over year.
What was GILD's earnings growth in the past year?
As of Gilead Sciences's earnings date in Invalid Date, Gilead Sciences's earnings has grown 1,092.5% year over year. This is 978.01 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 114.49%. GILD earnings in the past year totalled $5.97 billion.
What are Gilead Sciences's earnings expectations?
The current EPS estimate for Gilead Sciences's earnings report in Invalid Date is $1.94.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.